Shaily Engineering Plastics Ltd

- There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. - The discussion highlights ongoing and planned capital expenditures, such as INR125 crores investment for expanding pen manufacturing capacity. - The company is funding expansions internally, with no indication of taking advances or funding from customers for capex. - Contracts with customers are generally take-or-pay, but no customer advances specifically for capex are being received. - Management indicates strategic expansion based on customer commitments but refrains from disclosing any fundraising plans publicly. - Confidentiality is maintained regarding any financial details related to customer contracts or funding. In summary, as per the transcript content on page 17 and surrounding pages, there is no disclosed plan or indication of new debt or equity fundraising at this time.

- INR125 crores capex planned over the next 12 to 18 months for expanding pen manufacturing capacity by 50 million units in two phases of 25 million each (Q2 FY ‘26 and Q1 FY ‘27). - Additional capacity expansion to reach an effective capacity of 70-75 million pens by early FY ’27. - No additional land required for current capex; expansions conducted on existing plant or new greenfield sites. - Focus on scaling up IP-led pen platforms, including new variants like semaglutide pens. - Strategic investments aligned with volume commitments from customers over the next 3 to 5 years. - Emphasis on innovation for next-generation drug delivery systems (e.g., connected drug delivery) targeting big pharma. - No advances taken from customers for capex; business agreements are based on volume commitments rather than upfront payments for capital costs.

- The Healthcare segment is expected to contribute significantly to revenue and profitability over the next couple of years. - Capacity expansion: Current effective pen manufacturing capacity to reach 70-75 million pens by FY '27, targeting 80-85% utilization. - Full utilization of expanded capacity by FY '28 is the target, contingent on product launches and customer approvals. - Significant growth anticipated from IP-led pen platforms, especially GLP-1 pens like semaglutide. - Ongoing discussions with multiple customers for volume commitments and capacity over next 3-5 years. - Continued investment in new technologies and innovations aiming at breakthrough drug delivery devices. - Pharma segment showing rapid growth with 181% YOY revenue increase, with supply to 2-3 pharma customers expected within 1-3 quarters. - Margins in services business expected to improve from current quarter due to ramp-up of development projects.

- Healthcare segment revenue grew 181% YoY in Q1 FY '26, driving overall strong revenue growth of 38% YoY. - EBITDA margin expanded significantly by 840 bps to 28.5%, with EBITDA nearly doubling YoY. - PAT increased by 136% YoY, with margin improvement of 700 bps. - Cash PAT grew 91% YoY, indicating strong cash flow generation. - Capacity expansions underway: additional 25 million pens by Q2 FY '26 and another 25 million pens by FY '27, aiming for total 70-75 million pen capacity. - Target utilization of new capacities by FY '28, focusing on GLP-1 pen platforms. - Investment of INR125 crores capex planned to support expansion and innovation. - Margins in services expected to improve from current quarter due to investment in innovation and scaling up. - Focus on targeting big pharma with next-gen drug delivery and connected devices, aiming for sustained growth over 7-10 years. - Overall, strong volume growth and margin expansion expected to continue, supporting robust earnings and EPS growth.

- Current capacity of 70 to 75 million pens (80-85% utilization) is based on customer commitments, with about 50-60% backed by firm take-or-pay contracts. - Capacity expansions aligned with signed contracts; further expansions will depend on new capacity contracts. - Discussions ongoing with multiple customers regarding volume commitments and capacity requirements for next 3-5 years. - Customers are negotiating increased capacity and buffer volumes to cater to potential market upside. - The orderbook visibility depends heavily on product launch timings and approvals; hence exact numbers are fluid. - No advances for capex are taken from customers; agreements are volume-based supply commitments. - Capacity utilization expected to ramp up fully by FY '28, contingent on product launches and market response. - Exhibit batches for pharma products like tirzepatide have been supplied in Q1 with ongoing supply expected within next 1 to 3 quarters to 2-3 customers.